Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase: Research paper

British Journal of Pharmacology

Volumn 159, Issue 7, 2010, Pages 1542-1547

  Miller, Thomas W ^a   Isenberg, Jeff S ^b   Roberts, David D ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cardiovascular disease; CD47; Nitric oxide; Soluble guanylate cyclase; Thrombospondin 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CD47 ANTIGEN; CYCLIC GMP; GUANYLATE CYCLASE; MESOPORPHYRIN; NITRIC OXIDE; THROMBIN; THROMBOSPONDIN 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; SWINE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE;

BLOOD PLATELETS; CELLS, CULTURED; CYCLIC GMP; ENZYME ACTIVATION; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HUMANS; MUSCLE, SMOOTH, VASCULAR; PLATELET AGGREGATION; THROMBOSPONDIN 1;

EID: 77949831857     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00631.x     Document Type: Article

References (47)

1. Arnold WP, Mittal CK, Katsuki S, Murad F (1977). Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74 :3203 3207.
2. Booth WJ, Berndt MC (1987). Thrombospondin in clinical disease states. Semin Thromb Hemost 13 :298 306.
3. Buechler WA, Ivanova K, Wolfram G, Drummer C, Heim JM, Gerzer R (1994). Soluble guanylyl cyclase and platelet function. Ann N Y Acad Sci 714 :151 157.
4. Burstyn JN, Yu AE, Dierks EA, Hawkins BK, Dawson JH (1995). Studies of the haeme coordination and ligand binding properties of soluble guanylyl cyclase (sGC): characterization of Fe(II)sGC and Fe(II)sGC(CO) by electronic absorption and magnetic circular dichroism spectroscopies and failure of CO to activate the enzyme. Biochem 34 :5896 5903.
5. Challah M, Nadaud S, Philippe M, Battle T, Soubrier F, Corman B et al. (1997). Circulating and cellular markers of endothelial dysfunction with aging in rats. Am J Physiol 273 (4 Pt 2 H1941 H1948.
6. Chirkov YY, Chirkova LP, Horowitz JD (1996). Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn Schmiedebergs Arch Pharmacol 354 :520 525.
7. Chirkov YY, Horowitz JD (2007). Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther 116 :287 305.
8. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HHHW, Stasch J-P (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5 :755 768.
9. Favier J, Germain S, Emmerich J, Corvol P, Gasc JM (2005). Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J Pathol 207 :358 366.
10. Feelisch M (1998). The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 358 :113 122.
11. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF, Jr., Vita JA (1998). Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98 :1481 1486.
12. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G (2008). Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 48 :1400 1410.
13. Garthwaite J, Charles SL, Chess-Williams R (1988). Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336 :385 388.
14. Gerzer R, Bohme E, Hofmann F, Schultz G (1981). Soluble guanylate cyclase purified from bovine lung contains haeme and copper. FEBS Lett 132 :71 74.
15. Hu X, Feng C, Hazzard JT, Tollin G, Montfort WR (2008). Binding of YC-1 or BAY 41-2272 to soluble guanylyl cyclase induces a geminate phase in CO photolysis. J Am Chem Soc 130 :15748 15749.
16. Ignarro LJ, Kadowitz PJ (1985). The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol 25 :171 191.
17. Ignarro LJ, Ballot B, Wood KS (1984). Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem 259 :6201 6207.
18. Ignarro LJ, Adams JB, Horwitz PM, Wood KS (1986). Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-haeme exchange. Comparison of haeme-containing and haeme-deficient enzyme forms. J Biol Chem 261 :4997 5002.
19. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD (2005). Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 102 :13141 13146.
20. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD (2006a). CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281 :26069 26080.
21. Isenberg JS, Wink DA, Roberts DD (2006b). Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 71:785 793.
22. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M et al. (2007a). Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109:1945 1952.
23. Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC et al. (2007b). Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 27:2582 2588.
24. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L et al. (2007c). Increasing survival of ischemic tissue by targeting CD47. Circ Res 100:712 720.
25. Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG et al. (2008a). Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 173:1100 1112.
26. Isenberg JS, Roberts DD, Frazier WA (2008b). CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol 28:615 621.
27. Isenberg JS, Romeo MJ, Maxhimer JB, Smedley J, Frazier WA, Roberts DD (2008c). Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann Surg 247:860 868.
28. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J et al. (2008d). Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111:613 623.
29. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF et al. (2009a). Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 284:1116 1125.
30. Isenberg JS, Qin Y, Maxhimer JB, Sipes JM, Despres D, Schnermann J et al. (2009b). Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 28:110 119.
31. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY et al. (1986). Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 261:7236 7241.
32. Kharitonov VG, Sharma VS, Magde D, Koesling D (1999). Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Biochem 38:10699 10706.
33. Lamothe M, Chang FJ, Balashova N, Shirokov R, Beuve A (2004). Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site? Biochem 43:3039 3048.
34. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ (1981). Evidence for the inhibitory role of guanosine 3′, 5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57:946 955.
35. Mosher DF (1990). Physiology of thrombospondin. Annu Rev Med 41:85 97.
36. Munzel T, Daiber A, Mulsch A (2005). Explaining the phenomenon of nitrate tolerance. Circ Res 97:618 628.
37. Riessen R, Kearney M, Lawler J, Isner JM (1998). Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J 135 (2 Pt 1 357 364.
38. Rindone JP, Sloane EP (1992). Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother 26:515 519.
39. Roberts DD, Cashel J, Guo N-H (1994). Purification of thrombospondin from human platelets. Methods in Cell. Science 16:217 222.
40. Roth JJ, Gahtan V, Brown JL, Gerhard C, Swami VK, Rothman VL et al. (1998). Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res 74:11 16.
41. Sezaki S, Hirohata S, Iwabu A, Nakamura K, Toeda K, Miyoshi T et al. (2005). Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood) 230:621 630.
42. Snyder SH, Bredt DS (1991). Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 12:125 128.
43. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A et al. (2001). NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212 215.
44. Stone JR, Marletta MA (1994). Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochem 33:5636 5640.
45. Vanneste G, Dhaese I, Sips P, Buys E, Brouckaert P, Lefebvre RA (2007). Gastric motility in soluble guanylate cyclase alpha 1 knock-out mice. J Physiol 584 (Pt 3 907 920.
46. Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavanh B, Nolen GT et al. (2008). Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 57:432 439.
47. Zhao Y, Brandish PE, Ballou DP, Marletta MA (1999). A molecular basis for nitric oxide sensing by soluble guanylate cyclase. Proc Natl Acad Sci USA 96:14753 14758.